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Abstract 
 
A current challenge of in vitro genotoxicity testing is the issue of misleading positive 
results (low specificity). This has in the past led to unnecessary testing on laboratory 
animals, as results for agents testing positive for genotoxicity in vitro are often 
checked in vivo. Such misleading in vitro positives have predominantly been 
attributed to in vitro tests not accurately representing in vivo test systems, nor typical 
human exposure. Human exposure scenarios almost invariably involve low-level, 
chronic exposure, whereas in vitro testing uses predominantly high dose and acute 
exposures. Here, the issue of misleading positives was addressed using comparisons 
between traditional acute dosing and alternative, chronic dosing regimes, uniquely 
using low dose experiments. The In Vitro Micronucleus Assay was used to measure 
chromosome aberrations induced by methylating agents methyl methanesulphonate 
(MMS) and methyl nitrosourea (MNU) in human lymphoblastoid cell line, TK6. 
Quantitative RT-PCR was used to measure mRNA level induction of DNA repair 
enzymes. Lowest observed genotoxic effect levels (LOGELs) for MMS were obtained 
at 0.7µg/ml for the acute study and 1.0µg/ml for the chronic study. For acute MNU 
dosing, a LOGEL was observed at 0.46µg/ml, yet genotoxicity was completely 
removed following the chronic study. Interestingly, a statistically significant decrease 
was observed at 0.009µg/ml following acute MNU dosing. Levels of selected DNA 
repair enzymes did not change significantly at the dose range tested. However, p53-
deficiency (using the TK6 isogen cell line, NH32) increased sensitivity to MMS 
during chronic dosing, causing the LOGEL to equate to the LOGEL for acute dosing. 
Chronic dosing may prove an important in vitro alternative to the oversensitivity 
associated with acute dosing, leading to reductions in misleading positives and 
consequently, unnecessary in vivo tests.  
 
 
 
 
  
Introduction 
 
It is widely accepted that environmental mutagens that induce DNA damage are a 
potential cause of human cancers. Indeed, exposure to exogenous genotoxins occurs 
through a variety of sources, including food products, pharmaceuticals, cosmetics and 
pollutants. Currently, genotoxic effects of chemicals are assessed using a battery of 
regulatory-accepted in vitro assays, where a positive result for genotoxicity in vitro is 
often followed-up with in vivo tests (Pfuhler et al., 2010). However, a potential 
limitation of current in vitro assays is their relatively low specificity, meaning a 
propensity for generation of “misleading” or “false” positive results (Kirkland et al., 
2007, Pfuhler et al., 2010). Such irrelevant in vitro positives are those that are 
misleading when compared to their in vivo genotoxicity or rodent carcinogenicity 
counterpart data (Fowler et al., 2012). Consequently, misleading positives are 
unlikely to be relevant to humans in situ and lead to unnecessary animal tests. 
Another driver behind the requirement for the improvement of in vitro 
genotoxicity tests is the increasing pressure to limit the use of laboratory animals in 
toxicity testing. For example, the 7th Amendment to the Cosmetics Directive in 2009 
has meant that testing of cosmetics on animals is now banned in the European Union. 
Further, the European Centre for the Validation of Alternative Methods (ECVAM) 
workshops and government-funded National Centre for the 3Rs (NC3Rs) have 
encouraged the implementation of the 3Rs principle (replacement, reduction and 
refinement of animals in research) to support animal welfare in toxicity testing 
(Holmes et al., 2010). Indeed, Toxicity Testing in the 21st Century (TT21C) suggests 
that solely in vitro tests should be used. Considering such drivers, it is important to 
remember that current in vitro genotoxicity tests cannot satisfy the desire to rely more 
heavily on in vitro testing, as high rates of misleading positives will mean that some 
unnecessary in vivo follow up tests will be required. Therefore, it is crucial that 
dosing regime (Blakey et al., 2008) and cell type (Fowler et al., 2012) are carefully 
selected to maximize the representation of human exposure in vitro and, as a result, 
avoid false positives, improve in vitro testing per se, and reduce unnecessary animal 
testing.  
The high rate of unnecessary animal tests combined with the low specificity of 
in vitro tests is a reflection that current in vitro tests are failing to accurately 
recapitulate human exposure to genotoxins. This is partly due to high, acute dosing 
dominating in vitro testing (Blakey et al., 2008), while the majority of human 
exposures, and indeed exposures in in vivo tests involve longer-term, chronic dosing 
(Swenberg et al., 1987). This highlights the fact that current in vitro tests are unlikely 
to accurately portray the kinetics of DNA adduct formation and repair that operate 
during chronic dosing at subtoxic doses of chemical (Swenberg et al., 1987). It is, 
therefore, important to study subtoxic doses in vitro alongside toxic doses (Martin and 
Barrett, 2002). As well as being important for representation of human exposure in 
vitro, chronic dosing is also a valuable approach in cancer chemotherapy. For 
example, metronomic chemotherapy involves administration of regular and chronic 
doses of cytotoxic agent below the maximum tolerated dose (MTD) to optimally kill 
cancer cells, yet limit toxic side effects (Gasparini, 2001, Kerbel and Kamen, 2004). 
The cumulative dose with metronomic therapy might be significantly less than with 
MTD-based chemotherapy (Kerbel and Kamen, 2004), and is therefore likely to 
induce very different effects compared to the MTD. Therefore, characterization of 
effects of chronic dosing in cells may further current understanding of metronomic 
chemotherapy.  
Chronic dosing and dose-fractionation of low doses of genotoxin has not, to 
our knowledge, been extensively studied in vitro. However the effects of acute low 
doses have recently been investigated: a seminal publication from our laboratory 
(Doak et al., 2007) challenged the assumption that dose of genotoxin is always 
directly proportional to genotoxic effect. While induction of DNA adducts is 
predicted to be linear (Osterman-Golkar et al., 2003), the threshold dose-response for 
mutation obtained for some genotoxins confirms that cytoprotective mechanisms are 
crucial for limiting damage at low doses (Doak et al., 2007, Zaïr et al., 2011, Seager 
et al., 2012, Thomas et al., 2013, Brüsehafer et al., 2014, Chapman et al., 2014). 
Indeed, low doses of genotoxin may even invoke hormetic dose-responses (Touil et 
al., 2002, Gocke et al., 2009, Thomas et al., 2013), meaning that the default 
assumption of a linear dose-response is a gross oversimplification, leading to the 
exclusion of chemicals from products and treatments that are in fact safe, or even 
beneficial, at low doses. 
Not only is selection of in vitro dosing regime imperative, but also the 
selection of the cell type (Fowler et al., 2012). Traditionally, rodent cell lines have 
been used in genotoxicity testing, and these are known to be often p53-deficient 
(Fowler et al., 2012). p53-deficiency is associated with increased sensitivity to DNA 
damage, micronucleus induction and cytotoxicity when compared to p53-proficient 
cells, suggesting that a lack of p53 is contributing to misleading positive induction 
(Fowler et al., 2012). As p53 is crucial in the DNA damage response, it is preferable 
that p53-competent mammalian cells, such as cell line TK6, are used for assessment 
of genotoxicity (Fowler et al., 2012). Further, most healthy human cells in our bodies 
are p53 competent; therefore, the use of p53-competent cells in vitro is likely to better 
reflect human exposure. Here, we further explore the role of p53 deficiency on 
genotoxic dose responses.  
The alkylating agents constitute a class of compounds commonly utilised in 
genotoxicity studies, due to their defined DNA adduct profiles and high DNA-
reactivity under physiological conditions (Beranek, 1990, Jenkins et al., 2005). Such 
alkylators are prevalent in the environment, with sources of contact including 
cigarette smoke, food compounds and occupational exposure (Beranek, 1990). Due to 
their toxicity, methylating agents such as methyl methanesulphonate (MMS) and N-
methyl-N-nitrosourea (MNU) (Donelli et al., 1967) have been used as 
chemotherapeutic agents. Of these two potent genotoxins, MMS favours reaction with 
highly nucleophilic sites, such as the N7 site of guanine, which can induce 
clastogenicity and subsequent micronucleus formation (Beranek, 1990, Zaïr et al., 
2011). However, MNU is more mutagenic at the nucleotide level, inducing around 
27-fold greater levels of the highly mutagenic lesion O6-methylguanine than MMS 
(Beranek, 1990). Despite their ability to induce the same adducts, alkyl sulphonates 
and alkyl nitrosoureas have been shown to generate contrasting dose-responses for 
genotoxicity in vitro and in vivo (Doak et al., 2007, Gocke and Müller, 2009). This is 
likely to be partly determined by the different dynamics of DNA repair mechanisms 
operating for different adducts (Doak et al., 2008). For example, at doses below the 
no observed effect level (NOEL), O6-methylguanine-DNA methyltransferase 
(MGMT) repairs O6-methylguanine lesions (Doak et al., 2008, Thomas et al., 2013), 
whereas base excision repair initiated by N-methylpurine-DNA glycosylase (MPG) is 
important in repair of N7-methylguanine at such doses (Zaïr et al., 2011).  
The objective of the present study was to explore the effects of acute and 
chronic dosing of MMS and MNU within the low dose region, to further challenge the 
high-dose paradigm, help to refine in vitro testing design and to address the issue of 
false positives. A second aim was to investigate the mechanistic basis of the observed 
dose-responses, in terms of levels of DNA damaging agents and the influence of p53 
on the observed dose-response. 
 
 
 
  
Materials and Methods 
 
Chemicals. MMS and MNU were purchased from Sigma-Aldrich (Dorset, UK) and 
stored according to the manufacturer’s instructions. MMS was diluted in dH2O and 
MNU was diluted in DMSO (Fisher Scientific). Dilutions from a master stock were 
made freshly each day for MNU and on the day of seeding for MMS, and stored in 
the dark at 4oC. Chemicals were tested to ensure that a statistically significant 
reduction in micronucleus frequency did not occur following stock storage over 10 
days. 
 
Cell culture. The human lymphoblastoid cell lines TK6 and NH32 were cultured in 
RPMI 1640 medium (Life Technologies) supplemented with 1% L-glutamine (Life 
Technologies) and 10% donor horse serum (BDGentest, Oxford). The cells were 
maintained in culture at a density of between 1x105 and 1x106 cells/ml. 
 
In Vitro Micronucleus Assay. TK6 or NH32 suspensions (flasks of 10ml) with cells 
at 1x105 cells/ml were seeded for 24h at 37oC and 5% CO2. Each flask was dosed with 
appropriately diluted test chemical (100μl in total) and incubated for 24h, or 5x24h, as 
appropriate (Table i), under standard tissue culture conditions (37oC, 5% CO2). 
Medium containing chemical was removed by centrifugation and replaced with fresh 
medium. Treated cells were then harvested after a further 24h. Pellets were 
centrifuged for 8min at 1000 revolutions per minute (rpm) with phosphate-buffered 
saline (PBS, Invitrogen), centrifuged with 0.56% KCl for 10min at 800rpm, then 
fixed using methanol and acetic acid mixtures. Slides were prepared for analysis using 
the automated Metafer Slide Scanning Platform. The full protocol is outlined in 
Seager et al. (in press). Nuclei were then stained using DAPI and viewed under an 
Olympus BX50 Fluorescence Microscope. A total of 12,000 cells were scored per 
treatment for three replicates. 
 
Cytotoxicity measurement. A haemocytometer was used to count 10µl samples of 
cells on each day of the assay. Relative population doubling (%) (Fellows et al., 2008, 
Lorge et al., 2008) was then calculated as a measure of observed cytotoxicity. RPD 
did not decrease below 50% (RPD of 67.6% was the minimum) for any of the doses 
tested (Supplementary Figure 1), in line with the Organisation for Economic Co-
operation and Development (OECD) requirements for use of the In Vitro 
Micronucleus Assay.  
 
Table i. Example of the dose fractions of chemical administered to cells for a total 
dose of 2µg/ml, to demonstrate the dose-fractionation approach. The overall 
concentration quoted hereafter, represents a cumulative dose for the chronic studies. 
The “+2” nomenclature refers to two additional, non-dosing days: 1x 24h’s seeding 
and 1x 24h of recovery. 
 
Study Total number of 
doses 
Total dose 
(µg/ml) 
Dose/day (µg/ml) 
Acute (1+2 day) 1 2 2 
Chronic (5+2 day) 5 2 0.4 
Chronic (10+2 day) 10 2 0.2 
 
 RNA isolation and quantitative real time-PCR. RNA was extracted from treated 
cell samples using RNeasy Mini Kit (Qiagen) and RNase-free DNase I Set (Qiagen) 
using the recommended protocols and for various time points and concentrations. 
Synthesis of cDNA from RNA was completed using Quantitect Reverse Transcription 
Kit (Qiagen). qRT-PCR was performed using these samples, using Quantifast 
SYBRGreen I (Qiagen) and appropriately designed and optimised primers, or for 
MGMT, TaqMan® probe PCR (Qiagen) was used. A BioRad iCycler was used to 
perform the real-time PCR and analysis was completed using BioRad iQ5 software. 
 
O6-benzylguanine (O6BG). Cells were treated with the MGMT inhibitor, O6BG 
(Sigma-Aldrich) dissolved in methanol (Fisher Scientific). Dosing was performed for 
1h at 37oC, 5% CO2, with a final concentration of 10µM, prior to dosing with MNU. 
 
Protein isolation and immunoblotting. Cell suspensions were centrifuged at 
1200rpm and washed twice in 4oC phosphate-buffered saline (PBS) (Gibco). Cells 
were lysed at 4oC using 1x radioimmuno-precipitation lysis buffer (RIPA) (Sigma-
Aldrich) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and kept on 
ice for 5 min prior to vortexing followed by centrifugation at 10,000 revolutions per 
minute for 10 min at 4°C. Protein concentration was determined using the DC 
quantification assay (Biorad). Proteins (40µg) were mixed at a 1:1 ratio with 1x 
Laemmli buffer (Sigma-Aldrich) and resolved on a 12% (MPG) or 10% (p53) SDS 
polyacrylamide gel. Proteins were then electroblotted onto Immun-Blot PVDF 
membranes (Biorad) and blocked for 1h with 1x Tris-buffered saline-Tween 20 
containing 5% bovine serum albumin (BSA) (Sigma-Aldrich). Membranes were 
separated and probed with MPG antibody (1:1000 dilution; M6195; Sigma-Aldrich) 
or p53 antibody (1:1000 dilution; p53: 9282, phosphoser15-p53: 9284. Cell Signaling) 
diluted in 5% BSA at 4°C overnight. After four washes with 1x Tris-buffered saline-
Tween 20 containing 5% BSA, rabbit anti-mouse secondary antibody was used at 
1:10,000 dilution (ab6728-1, abcam) for MPG and goat anti-rabbit secondary 
antibody (ab6721, abcam). The membrane incubated for a further hour prior to three 
washes with 1x TBS-Tween 20 containing 5% BSA. To correct for protein loading 
differences, blots were probed with mouse antibody to ß-actin (ab8226-100, abcam), 
followed by rabbit anti-mouse secondary antibody. Immun-Star WesternC 
Chemiluminescence Kit (Biorad) was used for the immunodetection of proteins. Band 
densitometry was determined using the Quantity One software (Biorad). 
 
Statistical analysis. Data was square root (√) transformed prior to the performance of 
a Dunnett’s 2-sided post hoc analysis to identify the first statistically significant 
increase above control levels (i.e., lowest observed effect level (LOEL)).  
 
 
 
  
Results 
 
Chronic dosing reduces micronucleus frequency relative to acute dosing  
 
Dose-responses for matched chronic 5+2 day exposure and acute 1+2 day exposure to 
MMS and MNU, were generated in TK6 cells using the In Vitro Micronucleus Assay, 
coupled to high-powered acquisition of data through use of a semi-automated image 
analysis system (Metafer, Zeiss). Concentrations of chemical were selected based on 
those used in previous studies (Doak et al., 2007) in AHH-1 human lymphoblastoid 
cells. The mononucleate assay was used, rather than the cytokinesis block 
micronucleus (CBMN) assay, due to the study duration being over several days. 
Following a positive response in the acute 1+2 day study with MMS and MNU, the 
same dose range, fractionated, was employed for the 5+2 day study (Figure 1).  
 
To explore alternative dosing regimes, chronic dosing of TK6 cells was 
performed over a five-day period with MMS or MNU (Figure 1 C, D). RPD values, 
indicating cytotoxicity levels, are shown in Supplementary Figure 1. The LOGEL, 
or first statistically significant increase in micronucleus frequency above control 
levels, increased from 0.7µg/ml for the acute MMS study to 1.0µg/ml for the chronic 
5+2 day MMS study. The LOGEL for the acute MNU study was 0.46µg/ml, whereas 
no LOGEL was observed for the chronic study in the dose range tested. Therefore, 
chronic dosing caused the LOGEL to shift to the right along the x-axis for both 
chemicals with respect to acute dosing. A 10+2 day study was also performed with 
MMS (Supplementary Figure 2), where genotoxicity was removed completely for 
the dose range of MMS tested. This supports the notion that acute dosing is overly 
sensitive. 
 
Statistical analysis was performed on the data that produced a LOGEL, i.e., 
acute 1+2 day MMS and MNU, and chronic 5+2 day MMS. The results 
(Supplementary figure 3) implied that threshold dose-responses were a possibility 
for MMS, whereas the dose-response was determined to be linear for the acute MNU 
study. Further investigation suggested that micronuclei accumulated over time during 
the chronic 5+2 day MMS study for 2.0µg/ml, a dose above the LOGEL 
(Supplementary figure 4). 
 
 
 
 
Figure 1. Influence of MMS (A, C) and MNU (B, D) dose on micronucleus frequency for 
acute 1+2 day (A, B) and chronic 5+2 day (C, D) treatments in TK6 cells (n=3). Points, mean 
of treatments in triplicate; bars, SD. The x axes represent cumulative dose for the chronic 
studies. For MMS, the first statistically significant increases in micronucleus frequency above 
solvent control (LOGELs) were at 0.7μg/ml (p=0.007) for acute exposure and 1.0μg/ml 
(p<0.001) for chronic exposure. The first statistically significant increase in micronucleus 
frequency for MNU acute was observed at 0.46µg/ml (p=0.007), whereas no significant 
differences were observed for the 5+2 day treatment (p≥0.89). Micronucleus frequency (%) 
represents the percentage of mononucleated cells containing one or more micronuclei. * 
p≤0.05; ** p≤0.01; *** p≤0.001. LOGELs are indicated by arrows. 
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p53 deficiency increases the sensitivity to MMS during chronic dosing 
 
p53 is an important mediator in the DNA damage response and is mutated in many 
human cancers. p53 has previously been implicated in the BER pathway (Seo et al., 
2002), which is strongly associated with repair of lesions induced by alkyl 
sulphonates (Kaina, 1993). Therefore, the chronic 5+2 day study with MMS was 
repeated using the p53-deficient cell line, NH32, which is isogenic to TK6 (WT p53), 
to observe how p53 influences micronucleus induction. MMS was selected due to a 
LOGEL having been identified in the chronic 5+2 day study, which enabled a 
quantitative comparison between the different cell lines for the same chemical, unlike 
with MNU.  
 
The LOGEL for MMS in NH32 cells was reduced relative to TK6, from 
1.0µg/ml in TK6, to 0.7µg/ml in NH32 (Figure 2A). Interestingly, the NH32 chronic 
LOGEL occurred at the same dose as for the acute MMS study in TK6, which was 
also 0.7µg/ml. With increasing dose of MMS in NH32 cells, micronucleus frequency 
increased more rapidly compared to TK6, with NH32 reaching a maximum of 8.07% 
micronucleated cells at 2µg/ml, whereas for the same MMS dose, TK6 cells 
demonstrated an almost threefold lower induction of 2.96%. The p53 deficient cells 
were also more sensitive to cytotoxicity. At day 7, the RPD value for TK6 at 2µg/ml 
was 84.3% of control, whereas greater cytotoxicity was observed for NH32, where the 
RPD value was 60.3% (Supplementary Figure 5A). Interestingly, the untreated 
control micronucleus frequency for NH32 following the chronic regime, 1.7%, was 
around 2.5-fold greater than that of TK6, 0.69%. Interestingly, the basal micronucleus 
level for acute studies in NH32 was less than 1% (Brüsehafer et al., 2014), which was 
lower than the 1.7% obtained with the chronic regime. 
 
To further investigate the role of p53 in chronic dosing with MMS, Western 
blotting for detection of total p53 and phosphoser15-p53 was performed in TK6 
(Supplementary Figure 5B). The blots confirmed the presence of p53 in TK6, 
although produced no evidence of high p53 activation. A double-band was observed 
at 53kDa for phospho-p53, perhaps owing to multiple phosphorylated forms of p53 
present in the sample. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. p53-deficiency increased sensitivity to MMS during the chronic 5+2 day study, 
although p53 protein levels remained unchanged in p53-proficient TK6 (Supplementary 
Figure 5B). Micronucleus frequency (%) following chronic 5+2 day dosing with MMS in 
NH32 cells, as compared to the chronic 5+2 day study in TK6 cells (as presented in Figure 
1C). For NH32, the first statistically significant increase was observed at 0.7µg/ml (p=0.026). 
Doses 0.9, 1.0 and 2.0µg/ml for NH32 are in duplicate and error bars and asterisks are 
therefore excluded.  
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Chronic dosing with MMS did not increase sensitivity to DNA damage 
 
In order to determine whether the chronic dosing regime led to adaptation of the TK6 
cells through enhanced DNA repair enzyme expression, we analysed the mRNA 
expression of four DNA repair genes during the chronic dosing period (Figure 3). 
MMS was selected as this agent generated both a LOGEL and NOGEL for the 
chronic exposure.  
 
No significant changes in gene expression were observed, although DMC1, 
MPG and XRCC3 demonstrated similar trends in terms of DNA repair gene 
expression changes. For example, expression of all three genes increased at day 6, 
following a cumulative dose of 1µg/ml MMS. Further, expression peaked for these 
genes at day 4, following 0.5µg/ml treatment. Real-time DNA repair PCR arrays were 
used for initial assessment of differences between mRNA levels for 84 different DNA 
repair genes (data not shown). The arrays suggested a slight decrease in RAD51L1 
expression with chronic 5+2 day MMS treatment, and RAD51L1 was therefore 
selected for subsequent real-time PCR analysis. Although this produced no 
statistically significant changes in RAD51L1 expression, 0.5 and 1.0µg/ml levels 
were less than untreated control levels (Figure 3C). Similarly, the remaining three 
genes produced no statistically significant changes in mRNA expression, although a 
general increasing trend was observed with increasing number of days for 1.0µg/ml 
for all genes, whereas expression at 0.5µg/ml peaks at day 4 prior to decreasing at day 
6.  
 
MGMT (O6-methylguanine-DNA methyltransferase) levels were also 
analysed (data not shown), as MGMT is involved in the direct reversal of methylation 
of O6-methylguanine lesions (Kaina et al., 2007). However, accurate assessment of 
MGMT expression was not possible, as TK6 cells express MGMT at barely 
detectable levels (Hickman and Samson, 2004). This has also been observed 
previously in our laboratory. 
 
  
 
 
Figure 3. mRNA levels remained unchanged during the chronic 5+2 day study with MMS. 
Expression of mRNA of four DNA repair genes, normalized against housekeeping gene, ß-
actin, as determined by qRT-PCR. The time points and doses selected during the chronic 5+2 
day study with MMS did not produce any statistically significant differences. Gene products 
of DMC1 (Disrupted meiotic recombinase 1), RAD51L1 (RAD51 (S. cerevisiae)-like 1, 
synonymous with RAD51 homolog B) and XRCC3 (X-ray repair complementing defective 
repair in Chinese hamster cells 3) are involved in DNA double strand break repair. MPG (N-
methylpurine-DNA glycosylase) is involved in base excision repair (BER). 
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Discussion 
 
Exploration of chronic dosing regimes in vitro in the low dose region may be helpful 
for a comprehensive understanding of the effects of chemicals without bias towards 
high, acute doses. Such dosing regimes are important for safety assessment of 
chemicals on the basis that this type of dosing better represents human exposure 
levels than standard in vitro assays. This is particularly important if the oversensitivity 
of current in vitro tests is to be addressed. Chronic dosing may also provide further 
information on the effects of metronomic chemotherapy, the direct effects of which 
are difficult to determine in vivo. 
 
In this study, we have demonstrated that dose-fractionation of two methylating 
agents led to substantial reductions in micronucleus frequency, relative to 
comparative acute dosing. Dose-fractionation was associated with the eventual 
removal of genotoxicity for both MMS and MNU within the tested dose range 
(Figure 1, Supplementary Figure 2). Previously, dose-fractionation of a mutagenic 
dose to smaller doses has produced similar effects in vivo for both MMS (Tang et al., 
in preparation) and its ethyl form, ethyl methanesulphonate (EMS) (Gocke et al., 
2009, Gocke and Müller, 2009). In these studies, dose-fractionation abolished 
mutagenic effects of these chemicals in vivo. Interestingly, Gocke et al. (2009) 
observed in vivo that dose-fractionation produced an additive effect with N-ethyl-N-
nitrosourea (ENU)-induced mutation, whereas doses of EMS, which gave a threshold 
dose-response, did not lead to an accumulation of mutation (Gocke and Müller, 2009). 
This supports the trends observed here for MMS, where the probable explanation for 
a lack of accumulation lies in the combination of cellular DNA repair activity (Doak 
et al., 2007) and intervals between doses enabling time for repair (Tang et al., in 
preparation). However, for MNU, accumulation of damage was not observed for the 
5+2 day study relative to acute. Rather, damage induction was lost following chronic 
exposure, suggesting that under certain conditions, MNU’s genotoxic potency is 
removed. This is in part supported by in vitro data demonstrating a mutagenic 
threshold for MNU (Pottenger et al., 2009) and even possible hormetic effects 
(Thomas et al., 2013) at low doses of MNU. Such findings support a possible safe 
exposure at low levels of MNU, probably based on efficient DNA repair. The effect 
of MNU perhaps depends on the nature of the biological system, including repair 
capacity and MNU efficacy and metabolism, although this would require further 
investigation. However, in the context of this study, it would be expected that time for 
repair between doses would reduce genotoxicity regardless of chemical type. Equally, 
the longer recovery period in this assay, due to no cytokinesis block stage, may allow 
continued repair of DNA adducts. 
 
 As mentioned previously, it is likely that differences observed in genotoxicity 
between chronic and acute exposure regimes can be attributed to the extent of DNA 
repair pathway saturation (Doak et al., 2007) and the number of adducts that, 
therefore, remain unrepaired. Here, we did not observe significant changes in DNA 
repair mRNA levels during the chronic 5+2 day MMS study. This interesting result 
suggests that cells were as repair competent at assay commencement as at the end of 
the assay. This perhaps owes to the low doses tested, with adducts generated being 
repaired by basal levels of DNA repair enzymes (Doak et al., 2007), particularly 
below the NOGEL. It is important to note that mRNA analysis, as used here, does not 
inform us of levels of protein activity and phosphorylation state, for example. This 
aspect would be important to consider in follow up studies. We also hypothesise that 
the time between doses allows DNA repair to occur, limiting pathway saturation. 
Therefore, the cell might not be required to invest resources in up-regulation of DNA 
repair activity. Alternatively, different pathways to those investigated could be 
responsible in this case, or timing of extraction may be important in determining the 
observed effect (Doak et al., 2008). Interestingly, at the chronic 5+2 day MMS 
LOGEL of 1.0µg/ml, no significant changes in repair enzyme expression were 
observed. However, this is supported by previous studies, which suggested that 
different repair mechanisms operate at high doses and low doses for the same 
chemical (Doak et al., 2008, Zaïr et al., 2011). 
 
Secondly, the unchanged levels of DNA repair enzymes suggest that repair 
mechanisms did not increase sensitivity to alkylating agents. This is important 
because at low doses, up-regulation of repair pathways may be more damaging than 
the chemical itself. For example, over-expression of MPG has been associated with 
increased sensitivity to chromosome damage and increased cell death, due to the 
error-prone nature of the base excision repair pathway (Ibeanu et al., 1992, 
Coquerelle et al., 1995, Fishel et al., 2003, Rinne et al., 2004, Rinne et al., 2005, 
Fishel et al., 2007). However, as MPG recognizes N7methylguanine adducts 
(O'Connor and Laval, 1991), it was unexpected that MPG expression would remain 
unchanged throughout the chronic MMS 5+2 day treatment. However, Doak et al. 
(2008) similarly observed no change in MPG expression in response to MMS in 
AHH-1 cells, which was suggested to relate to MPG being tightly regulated to avoid 
unnecessary DNA damage.  
 
An alternative explanation for lack of change observed in repair gene 
expression is the timing of mRNA or protein extraction, or technique used for 
analysis. For example, p53 expression is predicted to occur in “waves” in response to 
genotoxic stimuli (Loewer et al., 2010), which would not necessarily be detectable 
when analyzing total protein expression as an average in a cell population. Further 
MGMT expression appears to occur as a single increase at around 4h post-dosing with 
genotoxin (Doak et al., 2008). Therefore, a continuous analysis method may be useful 
in future to ascertain precisely how DNA repair responds to chronic exposure and 
whether cells adapt to chemical. It is worth noting that only a small percentage of 
cells exhibit micronuclei, so it is possible that only these cells are responding to the 
treatment. 
 
The role of p53 in the chronic study was also investigated, as p53 is a crucial 
signaling node in the DNA damage response (Kastan et al., 1991), for example, in 
upregulating some DNA repair enzymes, as well as the TP53 gene encoding p53 
being mutated in a high proportion of human cancers (Greenblatt et al., 1994). We 
found p53-deficiency to confer heightened sensitivity to MMS, as adjudged by 
micronucleus induction and cytotoxicity (Figure 2, Supplementary figure 5A). This 
was unsurprising, as p53-deficiency has previously been associated with reduced 
growth arrest and DNA repair, and therefore a higher incidence of micronuclei 
(Masunaga et al., 2002, Driessens et al., 2003, Brüsehafer et al., 2014). Indeed, 
studies with DNA repair-proficient and -deficient Ames strains emphasised the 
importance of efficient DNA repair in genotoxic tolerance (Tang et al., 2014).  
Interestingly, protein levels of p53 and phosphoser15-p53 in p53-competent cell line 
TK6 remained unchanged during the chronic 5+2 day study. Doak et al. (2008) 
observed a similar effect, with levels of p53 remaining unchanged in response to low-
dose, acute MMS treatments. This would suggest that basal levels of p53 were 
sufficient under these dosing conditions to promote repair of DNA damage. Indeed, 
p53 protein levels are kept low during growth of normal cells through rapid protein 
turnover (Michael, 2003), to avoid both the down-regulation of the base excision 
repair pathway and excessive induction of apoptosis in response to increased p53 
levels (Offer et al., 2002).  
 
Conclusions 
 
We have observed that the use of dosing regimes more pertinent to human exposure 
than acute exposures may dramatically reduce the damage induced. Furthermore, low-
level, chronic dosing appears to minimally influence DNA repair mechanisms. 
Therefore, chronic dosing appears to limit cellular sensitivity to methylating agents, 
further supporting the theory of low dose tolerance in genetic toxicology. These data, 
therefore, suggest that dose-fractionation could be a valuable additional approach in 
in vitro testing for assessing the relevance of in vitro positive results. If chronic 
dosing can be incorporated into initial in vitro tests, this may lead to reductions in 
follow-up animal tests.  
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Supplementary figure 1. Relative population doubling (RPD (%)) values as a 
measure of cell survival relative to control levels for acute (1+2 day) (A, B) and 
chronic (5+2 day) (C, D) studies for MMS (A, C) and MNU (B, D), in TK6 cells.  
 
 
 
Supplementary figure 2. Micronucleus frequency (%) following a chronic 10+2 day 
treatment. Relative to the untreated control, there was no statistically significant 
increase in micronucleus frequency following treatment (p≥0.61). 
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Supplementary figure 3. Broken Stick Dose-Response Model used for prediction of 
probability of threshold dose-responses demonstrating statistically significant 
increases above control levels of micronucleus frequency. Acute (1+2 day) MMS 
inflection point = 0.3 μg/ml (p=0.07); chronic (5+2 day) MMS inflection point = 0.6 
μg/ml (p=0.07); acute (1+2 day) MNU inflection point = none (p=1), implying a 
linear dose-response, as determined by a t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 4. Micronucleus frequency measured at different time points 
(days 2, 4 and 6) throughout the chronic 5+2 day assay for 0µg/ml and 2µg/ml MMS 
treatments (n=1).   
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Supplementary figure 5. A. Relative population doubling (RPD (%)) values as a 
measure of cell survival relative to control levels for chronic (5+2 day) studies for 
MMS in NH32 cells. B. Western blots were performed for total p53 and phospho-p53 
(p-p53, ser15) expression, although no dose-dependent differences were observed 
over different time points and doses below and at the LOGEL. Examples of blots for 
0, 0.5 and 1.0µg/ml are shown for days 2 and 3, and similar results were obtained for 
the same doses at days 4 and 6. 
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